Michael Roost Clausen

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières et al. · Journal of Clinical Oncology · 2022 · 523 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings, Rogier Mous, Michael Roost Clausen et al. · The Lancet · 2021 · 337 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Kim Linton, Umberto Vitolo, Wojciech Jurczak et al. · The Lancet Haematology · 2024 · 139 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

Tarec Christoffer El‐Galaly, Chan Y. Cheah, Mette Dahl Bendtsen et al. · European Journal of Cancer · 2018 · 136 citations · Full text

Medicine, Neurology, Oncology +11

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Catherine Thiéblemont, Yasmin Karimi, Hervé Ghesquières et al. · Leukemia · 2024 · 119 citations · Full text

Medicine, Oncology, Hematologic Oncology +7